May 28, 2021 12:36 PM EDTUpdated 01:14 PM
Pharma
FDA+

Am­gen cracks the un­drug­gable code, earn­ing the FDA's nod for first-ever KRAS in­hibitor

Kyle Blankenship

Among the most fa­mous “un­drug­gable” tar­gets in on­col­o­gy is mu­tat­ed KRAS — a cell sur­face pro­tein tied to a range of ag­gres­sive can­cer types. Look­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times